PDL BioPharma to Announce First Quarter 2018 Financial Results on May 9, 2018
Conference Call Details
To access the live conference call via phone, please dial (800) 668-4132 from
To access the live and subsequently archived webcast of the conference call, go to the Company's website at http://www.pdl.com and go to "Events & Presentations." Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.
PDL seeks to provide a significant return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotech, pharmaceutical and medical device industries. In 2012, PDL began providing alternative sources of capital through royalty monetizations and debt facilities, and in 2016, PDL began acquiring commercial-stage products and launching specialized companies dedicated to the commercialization of these products. To date, PDL has consummated 17 of such transactions, of which nine are active and outstanding. PDL has one debt transaction outstanding, representing deployed and committed capital of
The Company operates in three segments designated as Income Generating Assets, Pharmaceutical and Medical Devices.
View original content with multimedia:http://www.prnewswire.com/news-releases/pdl-biopharma-to-announce-first-quarter-2018-financial-results-on-may-9-2018-300640727.html
Peter Garcia, PDL BioPharma, Inc., 775-832-8500, firstname.lastname@example.org; Jennifer Williams, Cook Williams Communications, Inc., 360-668-3701, email@example.com